cT1

1. CT-388 decreases cT1 in humans (-52 ms (8-95 ms)).

   “reduction in LFC by 59% (31%-86%) and cT1 by 52 ms (8-95 ms).”

   Human trialobesityliver22 mg24 weeksn = 27

   Effect of CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist, on Liver-Related MRI Parameters in Patients with Obesity

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on CT-388